Recursion Pharmaceuticals Inc 's Revenue per employee fell on a trailing twelve month basis to $ 113,720, below the company average number of $73,732. Within the Healthcare sector Employees of 463 other companies have achieved higher revenue per employee. While Recursion Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 1812 to 3344. Recursion Pharmaceuticals Inc has 600 employees.
Advancements in Drug Discovery and Microscopy Data: Recursion Pharmaceuticals Sets New StandardsIn an era where innovation and technological advancements are vital to the pharmaceutical industry, Recursion Pharmaceuticals continues to make significant strides that are redefining drug discovery and expanding the capabilities of foundational models. Recently, the company announced the release of OpenPhenom-S/16 in Google Cloud’s Model Garden, a revolutionary foundation model built on microscopy data, which has outperformed existing benchmarks such as CellProfiler. This achievement marks a pivotal shift in how computational biology intersects with drug development, further underscoring Recursion s position as a leader in the field.OpenPhenom is a non-commercial, publicly available foundation model that utilizes rich microscopy datasets to facilitate enhanced analysis in various biological research areas. By setting a new gold standard in data processing and interpretation, OpenPhenom is poised to significantly accelerate advancements in genomics and cellular biology, providing researchers with an unprecedented toolkit for understanding complex biological phenomena. Its capabilities are particularly vital in an era where precision medicine and targeted therapies are in high demand, enhancing the potential for breakthroughs in disease treatment.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
